Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Price drop

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Oct 19, 2023 8:52am

110 Views

Post# 35690503

RE:RE:RE:Price drop

ESMO is NOT going to be a game changer, just as ASCO was all but ignored. The answer for the SP drop is that investors are getting tired of waiting for news on an acquisition by or partnership with a MAJOR!!!! THAT'S IT!!! THATS ALL!!! The market is blass about a relationship with a not for profit. They want to hear about Roche or Merck or any BP.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing